CoChat

Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials

Open access

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

Background: We aim to understand whether all patients with hormonal receptor (HR)-positive (+)/human epidermal growth factor receptor-2 (HER2)-negative (−) metastatic breast cancer (MBC) should receive cyclin D-dependent kinase (CDK) 4/6 inhibitor-based therapy as a first-line approach. Methods: A network meta-analysis (NMA) using the Bayesian hierarchical arm-based model, which provides the estimates for various effect sizes, were computed. Results: First-line treatment options in HR+/HER2− MBC, including CDK 4/6 inhibitors combined with aromatase inhibitors (AIs) or fulvestrant (F), showed a significantly longer progression-free survival (PFS) in comparison with AI monotherapy, with a total of 26% progression risk reduction. In the indirect comparison across the three classes of CDK 4/6 inhibitors and F endocrine-based therapies, the first strategy resulted in longer PFS, regardless of specific CDK 4/6 inhibitor (HR: 0.68; 95% CrI: 0.53–0.87 for palbociclib + AI, HR: 0.65; 95% CrI: 0.53–0.79 for ribociclib + AI, HR: 0.63; 95% CrI: 0.47–0.86 for abemaciclib + AI) and patient’s characteristics. Longer PFS was also found in patients with bone-only and soft tissues limited disease treated with CDK 4/6 inhibitors. Conclusions: CDK 4/6 inhibitors have similar efficacy when associated with an AI in the first-line treatment of HR+ MBC, and are superior to either F or AI monotherapy, regardless of any other patients or tumor characteristics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers11111661

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart summarizing the process for the identification of the eligible studies.
Figure 1 The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart summarizing the process for the identification of the eligible studies.CC BY · PubMed Central
Figure 2 The network meta-analysis design: Network plot of the network meta-analysis. AI: Aromatase inhibitor.
Figure 2 The network meta-analysis design: Network plot of the network meta-analysis. AI: Aromatase inhibitor.CC BY · PubMed Central
Figure 3 Forest plots with direct comparisons against fulvestrant for progression-free survival, objective response rate, and clinical benefit rate. AI: Aromatase inhibitor.
Figure 3 Forest plots with direct comparisons against fulvestrant for progression-free survival, objective response rate, and clinical benefit rate. AI: Aromatase inhibitor.CC BY · PubMed Central
Figure 4 Forest plot on treatment effect for progression-free survival by subgroups in the indirect comparison between CDK 4/6 inhibitors, aromatase inhibitors, and fulvestrant. AI: Aromatase inhibitor; CT: Chemotherapy; ET: Endocrine therapy.
Figure 4 Forest plot on treatment effect for progression-free survival by subgroups in the indirect comparison between CDK 4/6 inhibitors, aromatase inhibitors, and fulvestrant. AI: Aromatase inhibitor; CT: Chemotherapy; ET: Endocrine therapy.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 70

Metadata

Authors
Rossi, V., Berchialla, P., Giannarelli, D., Nisticò, C., Ferretti, G., Gasparro, S., Russillo, M., Catania, G., Vigna, L., Mancusi, R. L., Bria, E., Montemurro, F., Cognetti, F., & Fabi, A.
Affiliations
  • Azienda Ospedaliera San Camillo-Forlanini (IT)
  • University of Turin (IT)
  • Instituto Nazionale Tumori Regina Elena (IT)
  • University of Rome Tor Vergata (IT)
  • Università Cattolica del Sacro Cuore (IT)
  • Candiolo Cancer Institute (IT)
  • Sapienza University of Rome (IT)
Corresponding author
Fabi, Alessandra
Venue
Cancers
Publisher
MDPI AG
Published
2019-10-26
Volume
11
Issue
11
Pages
1661
ISSN
2072-6694 (ISSN-L)
OpenAlex
W2981795130
Cited by
70
References
37
Citations by year
2026: 6 · 2025: 7 · 2024: 7 · 2023: 8 · 2022: 12 · 2021: 23 · 2020: 7
FWCI
1.77
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Pfizer
  • Celgene
  • Helsinn
Topics
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Keywords
HR-positive HER2-negative metastatic breast cancer, CDK4/6 inhibitors, first-line therapy, aromatase inhibitors, fulvestrant, palbociclib, ribociclib, abemaciclib, progression-free survival, endocrine therapy, soft tissue disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials. https://app.cochat.ai/papers/10.3390/cancers11111661
The paper
Rossi, V., Berchialla, P., Giannarelli, D., Nisticò, C., Ferretti, G., Gasparro, S., Russillo, M., Catania, G., Vigna, L., Mancusi, R. L., Bria, E., Montemurro, F., Cognetti, F., & Fabi, A. (2019). Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials. Cancers. https://doi.org/10.3390/cancers11111661

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.